ReviewCNS & neurological disorders drug targets2026
Natural Products Targeting Alzheimer's Disease via NF-κB Pathway: A Review.
Review in CNS & neurological disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's Disease (AD) is a severe neurological condition marked by cognitive decline and memory loss, affecting millions worldwide. Current therapeutic approaches for AD are primarily palliative, have slight effectiveness in arresting disease progression, and are frequently associated with significant adverse effects. In light of these limitations, there is a growing interest in exploring alternative medicinal strategies centred on phytogenic natural compounds. The nuclear factor kappa B (NF-κB) pathway is a critical biological target, essential for regulating the inflammatory response associated with the advancement of AD. Targeting the NF-κB signalling system is a promising approach for alleviating neuroinflammation and oxidative stress, although it operates in coordination with other pathways such as Nrf2 and MAPK, which also play significant roles in the complex pathophysiology of AD. This review provides a comprehensive analysis of the current studies about natural compounds and their potential therapeutic effects in AD, emphasising compounds obtained from various plant sources. We examine the mechanisms regulating the NF-κB pathway through the analysis of preclinical studies, evaluating its efficacy in reducing neurodegeneration and improving cognitive function in AD patients. Furthermore, future directions and conclusions have been incorporated, which jointly emphasise the significance of phytochemicals in modifying NF-κB and the associated signalling processes.
Indexed as
Identifiers
42841458What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.